Advertisement

Identification of Disease Biomarkers by Profiling of Serum Proteins Using SELDI-TOF Mass Spectrometry

  • Sigrun Langbein
Part of the Methods in Molecular Biology™ book series (MIMB, volume 439)

Abstract

Proteins are the main actors in all physiological and pathological processes. Since the final structure of the protein does not depend on the DNA sequence or even the mRNA sequence alone, the search for direct approaches on the proteome has gained great interest. The most complex and probably the largest proteome is serum, making it clinically the most important.

ProteinChip technology, in combination with modern mass spectrometry, allows the complex search for biomarkers, molecular interactions, signaling pathways, and the identification of novel therapeutic compounds. Here we describe the surface-enhanced laser desorption-ionization (SELDI) in combination with the time-of-flight (TOF) mass spectrometry for analyzing serum samples (SELDI was a patented technique from Ciphergen, Fremont, CA). Aluminum-based arrays contain chemical or biological surfaces allowing the capture of proteins, which interact with the surface. The bound proteins are laser desorbed and ionized for mass spectroscopy analysis. The differential mass spectral patterns reflect the protein expression bound on the chip surface and allow the comparison between various samples. Proteins of interest can be identified using peptide mass fingerprinting (PME).

Keywords

Surface-enhanced laser desorption-ionization (SELDI) time of flight (TOF) mass spectrometry (MS) serum ProteinChip fractionated serum biomarker peptide mass fingerprinting (PMF) 

Notes

Acknowledgments

I thank Dr. R. Bogumil for his helpful advice and constructive criticism.

References

  1. 1.
    1. Seet BT, Dikic I, Zho, MM, Pawson T (2006) Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 7:473–483CrossRefPubMedGoogle Scholar
  2. 2.
    2. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. CeU 100:57–70CrossRefPubMedGoogle Scholar
  3. 3.
    3. Gretzer MB, Partin AW, Chan DW, Veltri RW (2003) Modem tumor marker discovery in urology: Surface enhanced laser desorption and ionization (SELDI). Rev Urol 5:81–89PubMedGoogle Scholar
  4. 4.
    4. Ciordia S, de Los Rios V, Albar JP (2006) Contributions of advanced proteomics technologies to cancer diagnosis. Clin Transl Oncol 8:566–580CrossRefPubMedGoogle Scholar
  5. 5.
    Wiesner A (2004) Detection of tumor markers with ProteinChip technology Curr Pharm Biotechnol 5:45–67Google Scholar
  6. 6.
    6. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ (2005) Proteomic patterns: Their potential for disease diagnosis, Mol Cell Endocrinol 230:95–106CrossRefPubMedGoogle Scholar
  7. 7.
    7. Zhang H, Kong B, Qu X, Jia L, Deng B, Yang Q (2006) Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol 102:61–66CrossRefPubMedGoogle Scholar
  8. 8.
    8. Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright G L Jr, Drake RR, Vlahou A (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100:1814–1822CrossRefPubMedGoogle Scholar
  9. 9.
    9. Miguet L, Bogumil R, Decloquement P, Herbrecht R, Potier N, Mauvieux L, Van DA (2006) Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDl-TOF-MS. J Proteome Res 5:2258–2269CrossRefPubMedGoogle Scholar
  10. 10.
    Yip TT, Lomas L (2002) SELDI ProteinChip array in oncoproteomic research Technol Cancer Res Treat 1:273–280Google Scholar
  11. 11.
    11. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577CrossRefPubMedGoogle Scholar
  12. 12.
    12. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE (1997) Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res 57:4111–4117PubMedGoogle Scholar
  13. 13.
    13. Anderson NL, Anderson NG (2002) The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867CrossRefPubMedGoogle Scholar
  14. 14.
    14. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004) The human plasma proteome: A nonredundant list developed by combination of four separate source. Mol Cell Proteomics 3:311–326CrossRefPubMedGoogle Scholar
  15. 15.
    15. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD (2003) SELDI-TOF MS for diagnostic proteomics. Anal Chem 75:148A–155ACrossRefGoogle Scholar
  16. 16.
    16. Chapman K (2002) The ProteinChip Biomarker System from Ciphergen Biosystems: A novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 30:82–87CrossRefPubMedGoogle Scholar
  17. 17.
    17. Langbein S, Lehmann J, Harder A, Steidler A, Michel MS, Alken P, Badawi JK (2006) Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique. Technol Cancer Res Treat 5:67–72PubMedGoogle Scholar
  18. 18.
    18. Melle C, Ernst G, Schimmel B, Bleul A, Koscielny S, Wiesner A, Bogumil R, Moller U, Osterloh D, Halbhuber KJ, von Eggeling F. (2004) A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res 64:4099–4104CrossRefPubMedGoogle Scholar
  19. 19.
    19. Pusch W, Flocco MT, Leung SM, Thiele H, Kostrzewa M (2003) Mass spectrometry-based clinical proteomics. Pharmacogenomics 4:463–476CrossRefPubMedGoogle Scholar
  20. 20.
    20. Fung FT, Weinberger SR, Gavin E, Zhang F (2005) Bioinformatics approaches in clinical proteomics. Expert Rev Proteomics 2:847–862CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sigrun Langbein
    • 1
  1. 1.Department of Urology, Uro-Oncology, Academic Medic Centrum (AMC)University of AmsterdamAmsterdamThe Netherlands

Personalised recommendations